AU2002305140A1 - Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions - Google Patents

Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions

Info

Publication number
AU2002305140A1
AU2002305140A1 AU2002305140A AU2002305140A AU2002305140A1 AU 2002305140 A1 AU2002305140 A1 AU 2002305140A1 AU 2002305140 A AU2002305140 A AU 2002305140A AU 2002305140 A AU2002305140 A AU 2002305140A AU 2002305140 A1 AU2002305140 A1 AU 2002305140A1
Authority
AU
Australia
Prior art keywords
virions
membrane
compositions
methods
transepithelial transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002305140A
Inventor
Lou L. Houston
Philip L. Sheridan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizeke Pharmaceuticals Inc
Original Assignee
Arizeke Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizeke Pharmaceuticals Inc filed Critical Arizeke Pharmaceuticals Inc
Publication of AU2002305140A1 publication Critical patent/AU2002305140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
AU2002305140A 2001-04-03 2002-04-03 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions Abandoned AU2002305140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28127501P 2001-04-03 2001-04-03
US60/281,275 2001-04-03
PCT/US2002/010647 WO2002083840A2 (en) 2001-04-03 2002-04-03 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions

Publications (1)

Publication Number Publication Date
AU2002305140A1 true AU2002305140A1 (en) 2002-10-28

Family

ID=23076621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305140A Abandoned AU2002305140A1 (en) 2001-04-03 2002-04-03 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions

Country Status (2)

Country Link
AU (1) AU2002305140A1 (en)
WO (1) WO2002083840A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324778A2 (en) * 2000-10-02 2003-07-09 Arizeke Pharmaceuticals, Inc. Compositions and methods for the transport of biologically active agents across cellular barriers
WO2005014822A2 (en) * 2003-08-04 2005-02-17 Applied Research Systems Ars Holding N.V. Novel therapeutic fusion proteins
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
TW202122108A (en) * 2019-08-02 2021-06-16 美商健生生物科技公司 Materials and methods for multidirectional biotransportation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery

Also Published As

Publication number Publication date
WO2002083840A2 (en) 2002-10-24
WO2002083840A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
EP1391212A4 (en) Oral preparations and supports for oral preparations
HK1208446A1 (en) Derivatives of uk-2a uk-2a
AU2764801A (en) Enhanced transport of agents using membrane disruptive agents
AU2002257497A1 (en) Derivatives of exendin
AU2002304626A1 (en) Sterilization of surfaces
AU2002305140A1 (en) Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
IL158733A0 (en) Granular preparations of gaboxadol
AU2001271801A1 (en) Compositions and methods for producing recombinant virions
AU2002349443A1 (en) Preparations appropriate for cartilage tissue formation
AU2002332613A1 (en) Compositions and therapeutic methods for viral infection
AU2002350181A1 (en) Compositions and methods for viral delivery
AU2002213477A1 (en) Process for preparation of n-substituted 2-sulfanylimidazoles
AU2003239773A1 (en) Preparation of vaccines
AU2003268034A1 (en) Preparation of lansoprazole and related compounds
AU2002365353A1 (en) Synchronization of chroma and luma using handshaking
AU2002350154A1 (en) Preparation of polyethylene
AU2002216038A1 (en) Preparation of monofluoroalkenes
AU2002306376A1 (en) Isoindolines and process for preparation thereof
AU2002300773A1 (en) Preparation of Dialkylpyridylboranes
AU2002232061A1 (en) Compositions having improved bioavailability of eletriptan
AU2002307237A1 (en) Carboxybenzopyran derivatives and compositions
AU2002235525A1 (en) Preparation of n-methylparoxetine and related intermediate compounds
AU2002326818A1 (en) Methods for sterilizing preparations of glycosidases
AU2002251281A1 (en) Preparation of photomasks
AU2002341119A1 (en) Use of oligomeric proanthrocyanidins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase